Automated Ultrasound Cardiac Guidance Tool
Launched by ULTRASIGHT · Dec 5, 2022
Trial Information
Current as of August 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new tool designed to help doctors better analyze ultrasound images of the heart, known as echocardiograms. The goal is to see how well this automated guidance tool works with images taken from patients who have heart conditions. The trial is currently looking for participants, including both men and women aged 18 and older, who are willing to provide their consent to join the study.
To be eligible, participants should not have had any emergency admissions recently, and they should not be pregnant. They also need to be able to lie in specific positions during the ultrasound test. If you’re considering joining this study, you will have the opportunity to undergo an echocardiogram, which is a safe and common procedure, while contributing to important research that may improve heart imaging in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Males and females, aged 18 years and older
- • 2. Subject willing and able to give written informed consent
- Exclusion Criteria:
- • 1. Emergency (non-elective) admission within 24 h prior to participating in the study
- • 2. Female subjects who are pregnant (women of childbearing potential will provide a statement that they are not pregnant incorporated in the ICF
- • 3. Unable to lie as required in all the classic positions for standard TTE exam: supine on back / left decubitus
- • 4. Subjects who currently participate in a clinical trial, involving interventional cardiac devices.
- • 5. Subjects who have prior Echo exam with description of Low/Poor quality exam in the echo report.
- • 6. Subjects with BMI above 40.
- • 7. Subjects experiencing a known or suspected acute cardiac event.
- • 8. Subjects with severe chest wall deformity as per previous medical records and physical examination.
- • 9. Subjects who have undergone pneumonectomy.
- • 10. Subjects whose anatomy does not lend itself to yield diagnosable standard echocardiography clips (i.e., situs inversus with dextrocardia, single ventricle anatomy due to congenital heart disease, etc.).
About Ultrasight
Ultrasight is a pioneering clinical trial sponsor dedicated to advancing medical imaging technologies and enhancing diagnostic capabilities. With a focus on innovative ultrasound solutions, Ultrasight aims to improve patient outcomes through rigorous research and development, clinical validation, and strategic partnerships. The organization is committed to adhering to the highest ethical standards and regulatory compliance, ensuring the safety and efficacy of its products. By leveraging cutting-edge technology and a multidisciplinary approach, Ultrasight strives to transform the landscape of medical imaging and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Detroit, Michigan, United States
Patients applied
Trial Officials
Robert Ehrman, MD
Principal Investigator
Wayne University Emergency medicine
Noa Avisar, PhD
Study Director
UltraSight
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials